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Abstract
A number of small-molecule poly (ADP-ribose) polymerase (PARP) inhibitors are currently undergoing advanced
clinical trials. Determining the distribution and target inhibitory activity of these drugs in individual subjects, however,
has proven problematic. Here, we used a PARP agent for positron emission tomography–computed tomography
(PET-CT) imaging (18F-BO), which we developed based on the Olaparib scaffold using rapid bioorthogonal con-
jugation chemistries. We show that the bioorthogonal 18F modification of the parent molecule is simple, highly
efficient, and well tolerated, resulting in a half maximal inhibitory concentration (IC50) of 17.9 ± 1.1 nM. Intravital
imaging showed ubiquitous distribution of the drug and uptake into cancer cells, with ultimate localization within
the nucleus, all of which were inhibitable. Whole-body PET-CT imaging showed tumoral uptake of the drug, which
decreased significantly, after a daily dose of Olaparib. Standard 18F-fludeoxyglucose imaging, however, failed to
detect such therapy-induced changes. This research represents a step toward developing a more generic approach
for the rapid codevelopment of companion imaging agents based on small-molecule therapeutic inhibitors.
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Introduction
DNA breaks occur naturally during the course of each cell cycle. In
order for a cell to survive, however, these defects must be repaired.
Poly (ADP-ribose) polymerase (PARP) and breast cancer susceptibility
proteins (BRCA) are two proteins that have specific roles in repairing
such breaks, namely PARP repairs single-strand breaks and BRCA
repairs double-strand breaks. In cases where BRCA is mutated (i.e.,
not functional), PARP is able to repair both types of DNA breaks,
and thus, these cells depend solely on the PARP repair mechanism.
Small-molecule PARP inhibitors have received significant attention
when combined with DNA-damaging agents in BRCA-negative
tumors (synthetic lethality) [1]. Yet, despite the compelling scientific
rationale for the use of these agents as well as encouragement from
early clinical trials [1–3], more recent trials in triple-negative breast
cancers [4] and in ovarian cancer [5] have resulted in disappointment.
One issue in these studies has been the lack of clearly defined molec-
ular biomarkers of efficacy. Indeed, recent trials have been heavily re-
liant on indirect measures of cancer regression derived from RECIST
(Response Evaluation Criteria In Solid Tumors), tumor volumetrics
or plasma biomarker methods (CA125, circulating cancer cells). These
approaches could be considerably enhanced by the performance of
tandem measurements of drug distribution (pharmacokinetics) as well
as direct measurements of drug effects (pharmacodynamics) on their
intended target.
Using newer bioorthogonal approaches, a number of platform tech-
nologies have been recently introduced, which facilitate rapid labeling of
small-molecule drugs with 18F for rapid proof-of-principle preclinical
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imaging [6]. Although it is synthetically feasible to produce 18F-labeled
small-molecule PARP inhibitors, how these agents might behave in dif-
ferent cancers, particularly ovarian and pancreatic cancers, has remained
unclear. In the current study, we thus performed a more systematic
preclinical approach involving biologic validation studies in murine
models and using a prototype 18F radioactive and a fluorescent PARP
inhibitor platform based on the Olaparib (AZD2281) scaffold. The
18F bioorthogonally (BO)–labeled Olaparib (18F-BO) [6] and the fluo-
rescent analog (FL-BO) were then tested in mouse models of ovarian
and pancreatic cancer. We hypothesized that use of these BO agents
would allow quantitation of PARP expression levels in vivo. To test this
hypothesis, we designed a series of experiments that address the following
questions: 1) What is the imaging profile of 18F-BO in cancer models?
2) Do imaging signals from these agents correlate with PARP expression
levels in vivo? 3) Do the imaging agents colocalize with PARP inside
cancer cells? 4) How does 18F-BO imaging compare to 18F-FDG posi-
tron emission tomography (PET) imaging? Here, we show that 18F-BO
represents a highly selective agent for imaging PARP in vivo. Further-
more, 18F-BO allows accurate prediction of target inhibition (superior
to PET FDG imaging), and it has been found to accumulate inside
the nucleus of tumor cells. We anticipate that this class of agent will
be beneficial to current clinical trials not only by enabling directmeasures
of target occupancy but also for establishing drug doses based on biologic
rather than toxicity grounds and for identifying treatment failures.
Materials and Methods
Unless otherwise noted, all reagents were purchased from Sigma-
Aldrich (St. Louis,MO) and used without further purification. BODIPY
FL succinimidyl ester was purchased from Invitrogen (Carlsbad,
CA). Olaparib (AZD2281) was purchased from Selleck Chemicals
(Houston, TX). 4-[[4-Fluoro-3-(piperazine-1-carbonyl)phenyl]methyl]-
2H -phthalazin-1-one, AZD2281-Tz, 18F-TCO, and 18F-BO were
synthesized as described elsewhere [6–8]. [18F]-Fluoride (n.c.a.) and
18F-fludeoxyglucose (18F-FDG) were purchased from PETNET
Solutions (Woburn, MA). High performance liquid chromatography
electrospray ionization mass spectrometry (HPLC-ESI-MS) and high-
performance liquid chromatography (HPLC) purifications were per-
formed on a Waters (Milford, MA) LC-MS system. For LC-ESI-MS
analyses, a Waters XTerra C18 5 μm column was used. For preparative
runs, an Atlantis Prep T3OBD 5-μm columnwas used. High-resolution
ESI mass spectra were obtained on a Bruker Daltonics APEXIV 4.7-T
Fourier transform mass spectrometer (FT-ICR-MS) in the Department
of Chemistry Instrumentation Facility at the Massachusetts Institute of
Technology. Proton nuclear magnetic resonance (1H nuclear magnetic
resonance [NMR]) spectra were recorded on aVarianAS-400 (400MHz)
spectrometer. Chemical shifts for protons are reported in parts per
million (ppm) and are referenced against the dimethylsulfoxide lock
signal (1H, 2.50 ppm). Data are reported as follows: chemical shift,
multiplicity (s = singlet, d = doublet, t = triplet, m =multiplet), coupling
constants (Hz), and integration.
Synthesis of FL-BO
A solution of BODIPY FL succinimidyl ester (5.0 mg, 12.8 μmol)
in acetonitrile (250 μl) was added to a solution of 4-[[4-fluoro-3-
(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (4.7 mg,
12.8 μmol) and triethylamine (4.6 μl, 64.2 μmol) in acetonitrile
(250 μl). The reaction mixture was stirred for 4 hours at room tem-
perature and purified through HPLC to yield the title compound as
an orange solid (5.7 mg, 8.9 μmol, 70%). 1H NMR (400 MHz,
DMSO-d6) δ = 12.59 (s, 1H), 8.26 (d,
3JHH = 7.6, 1H), 7.96
(d, 3JHH = 7.8, 1H), 7.92-7.80 (m, 2H), 7.69 (s, 1H), 7.47-7.41
(m, 1H), 7.39-7.34 (m, 1H), 7.23 (t, 3JHH = 9.0, 1H), 7.09
(s, 1H), 6.45-6.38 (m, 1H), 6.30 (s, 1H), 4.33 (s, 2H), 3.66-3.05
(m, 10H), 2.80-2.68 (m, 2H), 2.48-2.44 (m, 3H), 2.26 (s, 3H);
19F NMR (376 MHz, DMSO-d6) δ = -119.4 (s, 1F), -142.8 (q,
JBF = 33 Hz, 2F); LC-ESI-MS(+) m/z = 621.4 [M − F]
+, 641.4
[M + H]+, 663.4 [M + H]+; LC-ESI-MS(−) m/z = 619.3 [M − 2H −
F]−, 639.3 [M − H]−; HRMS-ESI [M − H]+ m/z calculated for
[C32H33BF3N6O3]
+ 641.2671, found 641.2688 [M + H]+.
PARP-1 IC50 Determination
A commercially available colorimetric assay (Trevigen, Gaithersburg,
MD) was used to measure PARP-1 activity in vitro in the presence of
varying concentrations of FL-BO. Three-fold dilutions of FL-BO (final
concentrations ranging from 3.3 μM to 0.1 nM) were incubated with
0.5 U of PARP high specific activity (HSA) enzyme for 10 minutes in
histone-coated 96-well plates. All experiments were carried out in trip-
licate. Positive control samples did not contain inhibitor, and back-
ground measurement samples did not contain PARP-1. All reaction
mixtures were adjusted to a final volume of 50 μl and a final concen-
tration of 2% dimethyl sulfoxide (DMSO) in assay buffer. The remain-
der of the assay was performed according to the manufacturer’s
instructions. PARP-1 activity was measured by absorbance at 450 nm
in each well using a Tecan Safire2 microplate reader (Tecan Group,
Mannedorf, Switzerland).
Cancer Cell Lines
We chose a number of ovarian and pancreatic cancer cells lines
with variable PARP expression levels to correlate imaging findings
and because these primaries are the focus of ongoing clinical trials.
UCI 101, UCI 107, OVCA429, and A2780 cell lines were generously
provided by Dr Michael Birrer (Massachusetts General Hospital,
Boston, MA). All other cell lines were obtained from the ATCC
(Manassas, VA). MDA-MB-231, MDA-MB-436, MIA PaCa-2,
A2780, OVCAR429, UCI 101, and UCI 107 cells were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine serum,
L-glutamine, 100 IU penicillin, and 100 μg/ml streptomycin. RAW
264.7, PANC-1, CaOV3, andHT1080 cells were cultured inDulbecco
modified Eagle medium supplemented with 10% fetal bovine serum,
2% sodium bicarbonate, L-glutamine, 100 IU penicillin, and 100 μg/ml
streptomycin. SKOV-3 cells were cultured in McCoy 5A medium sup-
plemented with 10% fetal bovine serum, L-glutamine, 100 IU penicillin,
and 100 μg/ml streptomycin. OVCAR-3 cells were cultured in RPMI
1640 medium supplemented with 20% fetal bovine serum, 1% bovine
insulin, L-glutamine, 100 IU penicillin, and 100 μg/ml streptomycin.
OV-90 cells were cultured in 50%MCDB 105 medium, 50%medium
199 supplemented with 15% fetal bovine serum, and 2% sodium bi-
carbonate. All cell lines were cultured at 37°C and 5% CO2.
HT1080 H2B-Apple
pmApple-N1 (Myo1E-pmApple-C1; Addgene [Cambridge, MA],
Prof. Christien Merrifield [9]) was cloned by ligating mApple into
pmCherry-N1 (Clontech, Mountain View, CA) using AfeI and BsrG1
restriction enzymes, followed by ligation. The pTag-H2B-Apple con-
struct was produced by subcloning mApple from pmApple-N1 into
pTag-H2B-BFP (Evrogen, Moscow, Russia) using the AgeI and NotI
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restriction enzyme sites. Correct insertion of mApple was confirmed by
sequencing the insert in its entirety. pTag-H2B-Apple was transfected
into HT1080 cells using the X-tremeGENE HP transfection reagent
(Roche, Basel, Switzerland), followed by selection in 500 μg/ml
G418. Single clones were screened for H2B-Apple expression by fluo-
rescence microscopy. Cells were maintained in minimum essential
medium supplemented with 10% fetal bovine serum, 100 IU penicillin,
100 μg/ml streptomycin, 2 mM L-glutamine, nonessential amino acids,
and 100 μg/ml G418.
In Vitro Cell Assays
RAW264.7, PANC-1,MIAPaCa-2, A2780,OVCAR429,UCI 101,
UCI 107, SKOV-3, OVCAR-3, and OV-90 cells (200 μl, 35,000 cells/
ml) were each seeded in their respective growth medium on 96-well
plates and allowed to attach for 48 hours. After incubation with FL-BO
(2 μl, 100 μM, 20 minutes, 37°C), the medium was removed, and
the cells were subsequently washed (1× medium, 200 μl, and 2× 1×
phosphate-buffered saline [PBS]), fixed (4% paraformaldehyde in
PBS), and permeabilized (ice-cold PBS/0.1%TritonX-100/0.5%bovine
serum albumin [3× 200μl, 2× 5-minute and 1× 30-minute incubations]).
Cells were then incubated with anti–PARP-1/2 Pab (1:50; Santa Cruz
Biotechnology, Santa Cruz, CA) at 4°C overnight, washed with PBS/
0.1% Triton X-100 (3× 200 μl), and stained with secondary IgG-Cy5
Pab (1:100;Millipore, Billerica, MA) for 3 hours at 4°C. Before imaging,
cells were washed with PBS (1×, 200 μl), stained with both Hoechst
33342 (Invitrogen) and Cellomics blue whole cell stain (Thermo Scien-
tific, Waltham, MA) for 30 minutes at room temperature, and washed
again with PBS (3×, 200 μl). Imaging was performed on a DeltaVision
microscope (Applied Precision Instruments, Issaquah, WA) at 20×. For
each cell line, nine different areas were measured per well. Each cell line
was measured in biologic triplicate. FL-BO fluorescence for each cell line
was determined by quantifying the total fluorescence and by subtracting
the cells’ respective green autofluorescence. Relative PARP-1/PARP-2
expression levels were determined by quantifying the fluorescence signal
for each cell line and then subtracting unspecific secondary IgG-Cy5
Pab staining.
Mice
Experiments were performed in either C57BL/6 (B6) mice obtained
from the Jackson Laboratory (biodistribution, pharmacokinetics; n =
9) or in nu/nu mice obtained from Massachusetts General Hospital
(tumor implantations, imaging; n = 18). For all surgical procedures
and imaging experiments, mice were anesthetized with 2.0% isoflurane
in oxygen at 2.0 L/min. For imaging experiments lasting longer than
1 hour, the isoflurane flow rate was reduced to ∼1 L/min. Surgeries
were conducted under sterile conditions with a zoom stereomicroscope
(Olympus SZ61; Olympus America, Center Valley, PA). All procedures
and animal protocols were approved by the institutional subcommittee
on research animal care.
For window chamber imaging experiments, HT1080 cells (2 ×
106 cells, 50 μl 1× PBS) were implanted into dorsal skin chambers
(DSCs; APJ Trading Co, Inc, Ventura, CA) in the dorsal skinfold of
nu/nu mice as described before [10–14]. To allow neovascularization,
HT1080 tumors were allowed to grow for 8 days. Spacers between both
halves of the DSCs frame prevented excess compression of the tissue
and vessels.
To obtain standardized uptake values (SUVs) for 18F-BO, nu/nu
mice received four subcutaneous injections, each containing SKOV-3,
MIA PaCa-2, A2780, or PANC-1 cells, into their flanks and shoulders
(2.5 × 106 cells in 100 μl of 70:30 PBS/BD Matrigel [BD Biosciences,
Bedford, MA] per injection). Tumors were then allowed to grow for
2 weeks before imaging. For dose-response experiments, nu/nu mice
each received two subcutaneous injections containing A2780 cells
into the flanks (2.5 × 106 cells in 100 μl of 70:30 PBS/BD Matrigel
[BD Biosciences] per injection). Tumors were then allowed to grow
for 10 to 15 days before the start of imaging experiments.
Intravital Window Chamber Imaging
Mice with HT1080 tumors in their DSCs were injected with
75 nmol of FL-BO (7.5 μl of DMSO, 67.5 μl of N ,N -dimethyl-
acetamide/Solutol (1:1), 150 μl 1× PBS). Accumulation of the probe
in HT1080 tumor tissue was imaged in vivo in nu/nu mice as de-
scribed previously [11]. A custom-made dorsal skinfold chamber
holder was used to stabilize the sample and allow intravital imaging
of probe accumulation at single-cell resolution for hours. Static and
time series images were collected using a customized Olympus
FV1000 based on a BX61-WI confocal microscope (Olympus America).
A XLUMPLFLN 20× water immersion objective (NA 1.0) and a 60×
LUMFLN (NA 1.10) water immersion objective were used for data col-
lection (both Olympus America). FL-BO and H2B-Apple were scanned
and excited sequentially using a 473-nm and a 559-nm diode laser, re-
spectively, in combination with a DM405/488/559/635-nm dichroic
beam splitter. Emitted light was then separated and collected using an
SDM560 beam splitter and BA490-540 and BA575-675 band-pass
filters (all Olympus America). Control tumors were used to optimize im-
aging conditions by ensuring that no photobleaching or phototoxicity oc-
curred with the imaging settings used.
18F-BO Biodistribution Studies
B6 mice were used for blood half-life determinations. Mice were
administered 34 ± 5 μCi of 18F-BO by intravenous tail vein injection.
Blood sampling was performed by retro-orbital puncture using tared,
heparinized capillary tubes. Samples were subsequently weighed, and
activity was measured using an automatic gamma counter (Wallac
Wizard 3″ 1480 Automatic Gamma Counter; PerkinElmer, Waltham,
MA). Blood half-life data were fitted to a biexponential model (Graph-
Pad Prism 4.0c; GraphPad Software, Inc, San Diego, CA), and results
are reported as the weighted average of the distribution and clearance
phases. For biodistributions, B6 mice were intravenously injected
through the tail vein with either 43 ± 5 μCi (for the 2-hour time point)
or 410 ± 22 μCi (for the 18-hour time point) 18F-BO. Animals were
then sacrificed at 2 or 18 hours after injection, respectively. Tissues were
subsequently harvested andweighed, and their radioactivity was counted
using the PerkinElmer Wallac Wizard 3″ 1480 Automatic Gamma
Counter. Statistical analysis was performed using GraphPad Prism 4.0c.
PET–Computed Tomography Imaging
Mice were imaged with PET-computed tomography (CT) using
an Inveon small animal scanner (Siemens, Munich, Germany). Each
PET acquisition took approximately 25 minutes. A high-resolution
Fourier rebinning algorithm was used to rebin sinograms, followed by
a filtered back-projection algorithm to reconstruct three-dimensional
images without attenuation correction. Isotropic image voxel size was
0.796 × 0.861 × 0.861 mm, for a total of 128 × 128 × 159 voxels. Peak
sensitivity of the Inveon accounts for 11.1% of positron emission, with
a mean resolution of 1.65 mm. More than 100 counts were acquired
per pixel, and the mean signal-to-noise ratio was greater than 20.
Calibration of the PET signal with a cylindrical phantom containing
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18F isotopewas performed before all scans. CT images were reconstructed
from 360 cone-beam x-ray projections with a power of 80 keV and 500
μA. The isotropic resolution of the CT images was 60 μm. Reconstruc-
tion of data sets, PET-CT fusion, and image analysis were done using
IRW software (Siemens). Three-dimensional visualizations were pro-
duced using the DICOM viewer OsiriX (The OsiriX Foundation,
Geneva, Switzerland).
In Vivo Correlation Experiments
nu/numice bearing A2780 (left shoulder), PANC-1 (right shoulder),
MIA PaCa-2 (left flank), and SKOV3 (right flank) tumors were
injected with 480 ± 20 μCi of 18F-BO and subjected to PET-CT
imaging 2 hours after injection. After imaging, the mice were sacri-
ficed. The tissues were then harvested and weighed, and their radio-
activity was counted. After PET and CT image fusion, tumor SUV
margins were drawn to span the entire tumor. Drawings were guided
with the aid of the CT image using the Siemens Research Workplace
v3.0 analysis application.
Western Blot of PARP-1/PARP-2 Expression
After PET imaging and gamma counting, tumors were homogenized
in 400 μl of 1× radioimmunoprecipitation assay buffer and 2× Mini
Complete Protease Inhibitor Cocktail tablet (Roche, Indianapolis,
IN). The samples were spun at 4°C at 10,000 rpm for 10 minutes,
and the supernatant was collected. Protein concentration was measured
using a bicinchoninic acid protein assay according to the manufacturer’s
instructions (Thermo Scientific). Tumor lysate (10 μg) was loaded
onto NuPAGE Novex 4% to 12% Bis-Tris 1.0-mm gels, and electro-
phoresis was performed with the XCell SureLock Mini-Electrophoresis
system (both Invitrogen). Protein was transferred using the iBlot Dry
Blotting System to a nitrocellulose membrane (Invitrogen). The blot
was then blocked in 5% nonfat milk for 1 hour, washed with 1×
TBS–Tween 20 (Boston BioProducts, Ashland, MA), and incubated
overnight at 4°C with 1:1000 anti–PARP-1/2 in 5% nonfat
milk (Santa Cruz Biotechnology). After three 5-minute washes and
three 30-minute washes with 1× TBS–Tween 20, blots were incubated
with 1:5000 goat antirabbit horseradish peroxidase–conjugated sec-
ondary antibody ( Jackson ImmunoResearch, West Grove, PA) at
room temperature for 1 hour. After three 5-minute washes with
1× TBS–Tween 20, blots were incubated with SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific), exposed for 20 min-
utes, and then processed with the Kodak (Rochester, NY) X-OMAT
2000A processor. For glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) Western blots (after blocking and after three 5-minute
washes with 1× TBS–Tween 20), blots were incubated for 1 hour at
room temperature with 1:5000 anti–glyceraldehyde-3-phosphate dehy-
drogenase in 5% nonfat milk (R&D Systems,Minneapolis, MN). After
three 5-minute washes with 1× TBS–Tween 20, blots were incubated
with donkey antigoat horseradish peroxidase–conjugated secondary
antibody (Jackson ImmunoResearch,WestGrove, PA) at room tempera-
ture for 1 hour. After three 5-minute washes with 1× TBS–Tween 20,
blots were incubated with SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific), exposed for 10 seconds, and then pro-
cessed with the Kodak X-OMAT 2000A processor.
PET Imaging of Therapeutic Response
nu/nu mice bearing A2780 tumors were injected with 440 ± 40 μCi
of 18F-BO through the tail vein and subjected to PET-CT imaging
2 hours after injection. Thereafter, the same mice were reinjected with
18F-FDG (523 ± 47 μCi) and reimaged. After 18F-FDG imaging, the
mice were subjected to intraperitoneal injection of 1 mg of Olaparib
per mouse formulated in 1:1:4 DMAC/Solutol/PBS (100 μl). The next
day, mice were treated with 0.5 mg of Olaparib per mouse. Mice were
then imaged as they had been on the first day. This treatment/imaging
cycle was repeated for three more days, after which the animals were
sacrificed. A total of 10 complete serial sessions were acquired for each
mouse. Tumor SUV margins were drawn to span the entire tumor and
were accomplished with the aid of the CT images using the Siemens
Research Workplace v3.0 analysis application. SUV data from 18F-BO
PET images underwent decay correction to the start of 18F-FDG PET
imaging and used to correct 18F-FDG SUV data.
Results
Synthesis and Cellular Imaging
Before synthesis, we performed in silico modeling to determine
which sites of the Olaparib scaffold would tolerate modifications.
The docking platform [15] predicted (based on Penning et al.
[16]) that the 2H -phthalazin-1-one group of 18F-BO would behave
in an identical manner to that of Olaparib, namely by binding to the
PARP-1–active site (Figures 1A and W1A). The 4-NH -piperazine
functionality of Olaparib was shown to tolerate relatively bulky
substituents without significantly affecting PARP-1 binding affinity.
We thus modified this functionality through an NHS-ester reac-
tion either with BODIPY FL succinimidyl ester to yield FL-BO or
with tetrazine succinimidyl ester followed by 18/19F-trans-cyclooctene
to yield 18/19F-BO (Figure 2). The identity and purity of the imag-
ing agents were subsequently confirmed using NMR spectroscopy,
HPLC, ESI-MS and high-resolution mass spectrometry. Using a
PARP-1 activity assay, we then measured the IC50 values for FL-BO
(12.2 ± 1.1 nM) and 19F-BO (17.9 ± 1.1 nM), which are similar to
the one previously determined for Olaparib (AZD2281, 5 nM [7])
(Figures 1B and W1B).
Next, we determined the intracellular uptake and localization of
FL-BO. Figure 3A (Figure W2A) shows the typical staining patterns
for cell lines incubated with FL-BO, fixed, permeabilized, and then
costained with a PARP-1/2 antibody. The drug was found to localize
predominantly in the nuclei, particularly in the nucleoli of cells, co-
localizing with anti–PARP-1/2. The Pearson correlation coefficient
for PANC-1 cells between the PARP antibody stain and FL-BO
was Rcoloc. = 0.95. This correlation was similar for other ovarian
and pancreatic cancer cell lines tested. We subsequently investigated
whether the total cellular uptake of FL-BO correlated with PARP
protein levels. Using different cell lines, we found a good correlation
between PARP immunofluorescence and cellular FL-BO accumula-
tion (R2 = 0.858; Figures 3, B and C , and W2, B and C).
Intravital Imaging of FL-BO
We next used a well-established window chamber model to deter-
mine the kinetics and cellular distribution of FL-BO at single-cell
resolution in vivo [11]. Intravenous injection of FL-BO yielded a bright
green fluorescent signal, which quickly diffused through the vessels’
epithelial cells and resulted in a homogeneous nuclear staining of tumor
cells (Figure 4, top row). To determine whether cellular accumulation
could be inhibited in vivo, we also performed competition experi-
ments with nonfluorescent 19F-BO (500 μg injected 90 minutes before
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FL-BO). Figure 4 shows that the inhibitor resulted in a marked decrease
in uptake of the fluorescent imaging agent (Figure 4, bottom row).
Whole-Body Imaging of 18F-BO
The blood half-life for 18F-BO was determined through serial
bleeds, and the obtained data points were fitted using a biexponential
decay curve. The resulting weighted half-life for 18F-BO was t1/2 =
12.4 minutes, with R2 = 0.828 (Figure 5A). Biodistribution studies
at 2 hours after injection showed predominant hepatobiliary excre-
tion of 18F-BO (3.9 ± 0.9 and 3.1 ± 1.6%ID/g for liver and small
intestines, respectively; Figure 5C ) with low values in most other host
tissues. At 18 hours after injection, the highest amount of probe was
found in the feces (Figure 5D).
18F-BO was next used to image PARP expression in vivo. For this,
xenografts of four different human ovarian and pancreatic tumor
models (SKOV3, MIA PaCa-2, PANC-1, and A2780, with ascending
relative PARP expression profiles) were grown in nu/nu mice before
tumoral uptake of 18F-BO was determined through PET imaging
Figure 2. Synthesis of imaging fluorescent and PET active imaging agents. (A) Synthesis of FL-BO: a fluorescent marker for PARP expres-
sion in vitro and in vivo. (B) Synthesis of 18F-BO: a PET agent allowing to measure PARP expression noninvasively in vivo [6,8].
Figure 1. 18F-BO and FL-BO. (A) Binding model depicting 18F-BO and PARP-1, with the 2H -phthalazin-1-one binding to the catalytically
active site on PARP-1. (B) IC50 curves and values for
18F-BO (from Keliher et al. [8]) and FL-BO.
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(Figures 5B and W3). The resulting SUVs (Bq/ml) for each of the
four tumor types were subsequently quantitated by imaging and then
correlated to PARP expression data obtained by Western Blot analy-
sis. Trends for uptake values and Western blot analysis were similar,
with A2780 having the highest uptake and expression, followed by
PANC-1, MIA PaCa-2, and SKOV3 (Figures 5B and W3). Muscle
tissue had both the lowest accumulation of 18F-BO and the lowest
PARP expression.
Figure 4. Intravital imaging of FL-BO. Top row (without prior injection of 19F-BO): HT1080 H2B mApple cells (red), FL-BO (green), and
composite image. Bottom row (with prior injection of 19F-BO): HT1080 H2B mApple cells (red), FL-BO (green), and composite image.
Note the inhibition of FL-BO uptake into tumor cells in vivo.
Figure 3. Correlation of cellular FL-BO uptake and relative PARP expression. (A) In PANC-1 cells, there was an excellent correlation between
intracellular FL-BO distribution and PARP-1/2 expression: phase contrast (top left), anti-PARP (top right), FL-BO (bottom right), and Pearson cor-
relation coefficient of anti-PARP and FL-BO (bottom left). (B) Column representation of FL-BO uptake and anti-PARP immunofluorescence in
different cell lines. (C) Correlation of FL-BO uptake and anti–PARP-1/2 immunofluorescence (dashed line indicates the 95% confidence band).
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Finally, we determined whether 18F-BO could be used to measure
therapeutic drug inhibition in vivo. For these experiments, mice bear-
ing A2780 tumor xenografts were serially imaged both before and
after Olaparib treatment (Figure 6). Tumoral 18F-BO tumor-muscle
ratios were found to be significantly lower (P < .001) after single or
multiple doses of Olaparib than before treatment in the same animal.
As a comparison, we also obtained 18F-FDG scans to determine
whether similar effects would be seen. Interestingly, we observed
little change in tumor-muscle ratios of 18F-FDG after PARP treatment
(Figure 6).
Discussion
Our results show that, in ovarian cancer models, therapeutic doses
of Olaparib inhibit PARP in vivo and that target inhibition can be
quantitated by 18F-BO imaging within hours of initiating treatment.
Our experiments were designed to 1) validate 18F-BO for in vivo
PET imaging, 2) determine the robustness of our new imaging ap-
proach in different cancers, 3) directly compare 18F-BO imaging to
the clinical standard of 18F-FDG PET imaging (because many cancers
use glucose as an energy source [17,18]), and 4) determine the general
suitability of the described platform for codeveloping bioorthogonally
18F-labeled companion diagnostics for therapeutic inhibitors. Interest-
ingly, at the early time points investigated, therapeutic PARP inhibi-
tion had little effect on the 18F-FDG tumor/muscle imaging signal. In
contrast, 18F-BO imaging showed profound changes. These results
suggest that 18F-BO imaging could be of value to future clinical trials
of PARP inhibitors. Specifically, 18F-BO imaging could be used for
dose ranging, testing the comparative efficacy of combination treat-
ments, evaluating treatment efficacy across patient subpopulations,
and/or for enrolling (i.e., enriching for) likely responders to PARP
inhibitor clinical trials.
PARP inhibitors are a new class of agent that have shown a certain
amount of therapeutic efficacy, particularly in BRCA-related malig-
nancies, notably breast and high-grade serous ovarian cancers [4]. For
example, a phase 1 clinical study of Olaparib as a monoagent in breast
cancer patients with BRCA mutations provided support for the theory
of “synthetic lethality” [19]. In a follow-up study, in which the effects
of combination therapy were evaluated, resistance to platinum corre-
lated with decreased sensitivity to Olaparib [20]. However, a recent
phase 2 clinical trial (ICEBERG 1) [21], using RECIST criteria as the
metric of response, failed to show a dose response with Olaparib—
suggesting that tumor response to therapy occurs through an alternative
mode. In contrast, a more recent report demonstrated that adminis-
tration of single-agent Olaparib in ovarian cancer patients with BRCA
mutations was sufficient to induce tumor responses [5]. It is thus clear
that the clinical response to PARP inhibition is varied and that cur-
rently accepted markers of such response (progression-free survival,
RECIST, PARP inhibition in peripheral blood mononuclear cells, or
hair follicles) are insufficiently sensitive (i.e., indirect and/or late). The
availability of direct imaging tests capable ofmeasuring PARP inhibition
locally would thus be of enormous value in such settings.
The imaging agent used in the present study is based on the Olaparib
scaffold with bioorthogonal modifications on the cyclopropane end—
a region not essential for target binding [6,22]. Docking simulations
showed that 18F-BO, like Olaparib and several other newer PARP in-
hibitors, binds to the catalytically active region of PARP-1 through
its 2H-phthalazin-1-one group. The use of bioorthogonal 18F attach-
ment has several advantages over direct fluorination, namely 1) the
Figure 5. Pharmacokinetics of 18F-BO. (A) Blood half-life of 18F-BO after intravenous administration. (B) Correlation of PARP expression and
18F-BO uptake in four different ovarian and pancreatic tumor types as determined by immunoblot analysis. (C) Biodistribution of 18F-BO at
2 hours after intravenous administration. (D) Biodistribution of 18F-BO at 18 hours after intravenous administration.
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rapidity by which imaging agents can be developed, 2) the high syn-
thetic yields, 3) the clean reaction products, 4) the short synthesis times,
and 5) the ability to create companion fluorescent agents that can be
readily tested through microscopic imaging [23]. Each of these is im-
portant in the rapid preparation and validation of companion imaging
agents. Although companion imaging agents are structurally similar to
their parent inhibitors, they differ importantly in their dosage. Com-
pared with therapeutic doses, diagnostic doses of the imaging agent
were approximately 700 times lower for PET imaging and 5 times
lower for fluorescence imaging given the different inherent sensitivities
of these techniques. In other words, the imaging agent has negligi-
ble effects compared with repeatedly administering the therapeutic
parent compound.
We used a bioorthogonal approach to tag the small-molecule PARP
inhibitor with 18F and convert it into a companion imaging agent.
Orthogonal chemistry refers to a highly selective chemical reaction that
is both fast and able to take place within living systems. Specifically,
we used the trans-cyclooctene/tetrazine reaction because it is one of
the fastest and most selective chemistries available under physiologic
conditions. Additional advantages to this labeling platform include 1)
the high translatability of fluorescently and PET-labeled compounds,
2) the standardized synthesis of 18F-labeled bioorthogonal precursors,
and 3) the ability to rapidly screen potential targeted molecules of
interest. Despite these advances and their benefits, we believe that
18F-BO and other such bioorthogonal small-molecule inhibitors could
be improved further. For example, we anticipate the future use of
hybrid fluorescent PET/optical tags [24,25]. These would not only
enable the rapid translation of fluorescent targeted probes into PET
probes but would also allow use of chemically identical molecules with
both imaging modalities.
In summary, we describe a generic method for codeveloping
bioorthogonally 18F-labeled companion diagnostics for therapeutic
inhibitors. Using the example of PARP inhibition, we show that one
such agent is able to accurately measure PARP expression levels in vivo
and thus could be used as a tool to measure therapeutic inhibition
within a day of treatment initiation. These agent(s) will likely be of
value to the (pre)clinical testing of different PARP inhibitors as well
as hopefully other emerging small-molecule inhibitors.
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Figure W1. 18F-BO and FL-BO. (A) Binding model depicting 18F-BO and PARP-1, with the 2H -phthalazin-1-one binding to the catalytically
active site on PARP-1. (B) IC50 curves and values for
18F-BO and FL-BO (from Keliher et al. [8]).
Figure W2. Correlation of cellular FL-BO uptake and relative PARP expression. (A) In PANC-1 cells, there was an excellent correlation be-
tween intracellular FL-BO distribution and PARP-1/2 expression: phase contrast (grayscale), Hoechst 33342 (blue), anti-PARP (red), FL-BO
(green), composite image of anti-PARP and FL-BO, and Pearson correlation coefficient of anti-PARP and FL-BO. (B) Column representation
of FL-BO uptake and anti-PARP immunofluorescence in different cell lines. (C) Correlation of FL-BO uptake and anti–PARP-1/2 immuno-
fluorescence (blue line indicates the 95% confidence band).
Figure W3. Correlation of PARP expression and 18F-BO uptake in tumor tissue. (A) correlation of uptake and PARP expression in
four different ovarian and pancreatic tumor types as determined by immunoblotting. (B) coronal and axial CT and PET scans of a
representative A2780 tumor implanted in the shoulder of a mouse.
